APA (7th ed.) Citation

I, V., C, E., O, O., Y, C., E, M., O, G., . . . J, H. (2021). Editorial: Infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply. Alimentary pharmacology & therapeutics, 54(6), 848. https://doi.org/10.1111/apt.16569

Chicago Style (17th ed.) Citation

I, Visuri, et al. "Editorial: Infliximab or Adalimumab as First- or Second-line Anti-TNF-conflicting Evidence-authors' Reply." Alimentary Pharmacology & Therapeutics 54, no. 6 (2021): 848. https://doi.org/10.1111/apt.16569.

MLA (9th ed.) Citation

I, Visuri, et al. "Editorial: Infliximab or Adalimumab as First- or Second-line Anti-TNF-conflicting Evidence-authors' Reply." Alimentary Pharmacology & Therapeutics, vol. 54, no. 6, 2021, p. 848, https://doi.org/10.1111/apt.16569.